(Q38489591)

3 September 2017

Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy (English)

1 reference

3 September 2017

Annabelle Chow

1

1 reference

3 September 2017

Amy Wong

2

1 reference

3 September 2017

Giulio Francia

3

1 reference

3 September 2017

Shan Man

4

1 reference

3 September 2017

Robert S Kerbel

5

1 reference

3 September 2017

Urban Emmenegger

6

1 reference

3 September 2017

2 June 2013

1 reference

3 September 2017

13

1 reference

Investigational New Drugs

inferred from page(s)

published in

1 reference

3 September 2017

32

1 reference

3 September 2017

1

1 reference

3 September 2017

47-59

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-013-9974-3

3 September 2017

0 references

cites work

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Metronomic chemotherapy: new rationale for new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Significance analysis of microarrays applied to the ionizing radiation response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Nonreceptor tyrosine kinases in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Cancer predisposing mutations in BRCT domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Timeline: Chemotherapy and the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Resistance to chemotherapy: new treatments and novel insights into an old problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Managing drug resistance in cancer: lessons from HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9974-3

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

21 January 2018

1 reference

12 December 2020

Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model

1 reference

12 December 2020

Oral metronomic cyclophosphamide in elderly with metastatic melanoma

1 reference

12 December 2020

Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel

1 reference

12 December 2020

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models

1 reference

12 December 2020

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

1 reference

12 December 2020

Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy

1 reference

12 December 2020

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

12 December 2020

10.1007/S10637-013-9974-3

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference